Atopic dermatitis market seen reaching $19.53 billion by 2030

The global atopic dermatitis market is projected to grow from $11.34 billion in 2026 to $19.53 billion by 2030, driven by biologic drugs, JAK inhibitors and rising demand for personalized treatments. North America remains the largest market, while Asia-Pacific is expected to expand fastest.

Why it matters: - Atopic dermatitis is a chronic, non-contagious skin condition marked by dryness and itching, and effective long-term management remains difficult. - The market’s expected growth points to rising demand for therapies that can improve symptom control and reduce side effects. - The shift toward personalized medicine is reshaping treatment choices and pushing drug developers toward more targeted options.

What happened: - The Business Research Company said the atopic dermatitis market will grow from $11.34 billion in 2026 to $19.53 billion by 2030. - The forecast implies a 14.6% compound annual growth rate through 2030. - The market had been valued at $9.88 billion in 2025 and rose to $11.34 billion in 2026, equal to 14.8% growth. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Historic growth was supported by higher prevalence of chronic skin ailments, broader access to topical corticosteroids, expansion in dermatology services, greater awareness of eczema management and better diagnostic accuracy. - Future growth is expected to come from wider use of biologic drugs and JAK inhibitors. - Other drivers include more personalized dermatology treatments, more injectable therapies, higher investment in dermatological research and stronger demand for long-term symptom control. - Expected market trends include advanced topical formulations, targeted immunomodulators, stronger long-term disease management and more patient-centric treatment approaches. - The report’s 2026 edition includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The company said the report also includes key technologies and future trend analysis.

Between the lines: - Personalized medicine is emerging as a major growth engine because it aims to match treatments to a patient’s genetic and molecular profile. - In atopic dermatitis, that approach can help identify disease drivers more precisely and may improve outcomes while lowering side effects. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022, underscoring broader momentum behind tailored therapies.

What's next: - The market is expected to keep expanding through 2030 as biologics, JAK inhibitors and injectable therapies gain traction. - Regional growth is likely to tilt further toward Asia-Pacific as treatment access and dermatology demand increase. - The Business Research Company is offering a free sample report and the full market report through its website. - More information is available in the full report and the sample report.

The bottom line: - Atopic dermatitis is moving from a fast-growing niche market to a larger global treatment category, with personalized and targeted therapies driving the next phase of expansion.